Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk : Share repurchase programme

share with twitter share with LinkedIn share with facebook
share via e-mail
02/17/2020 | 09:04am EDT

On 5 February 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the 'Safe Harbour Rules').

This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.

Under the programme, initiated 5 February 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.9 billion in the period from 5 February 2020 to 4 May 2020.

Transactions related to Novo Nordisk's incentive programmes have resulted in a net transfer from Novo Nordisk of 252,288 B shares in the period from 5 February 2020 to 13 February 2020. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 50,828,493 B shares of DKK 0.20, corresponding to 2.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 13 February 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 760,000 B shares at an average share price of DKK 433.35 per B share equal to a transaction value of DKK 329,348,973.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).


Tel: +45 4442 3450

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
05:25aNOVO NORDISK A/S : - Rybelsus approved for the treatment of adults with type 2 d..
04/04Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2..
04/02NOVO NORDISK A/S : DTU increases Rigshospitalet's testing capacity
04/01NOVO NORDISK A/S : - Saxenda demonstrated improvements in BMI and body weight in..
03/30NOVO NORDISK A/S : - Share repurchase programme
03/27NOVO NORDISK AS : Ex-dividend day for final dividend
03/26NOVO NORDISK A/S : - Articles of Association
03/26Resolutions from the Annual General Meeting of Novo Nordisk A/S
03/26NOVO NORDISK A/S : Proxy Statments
03/23NOVO NORDISK A/S : Disclosure of transaction data
More news
Financials (DKK)
Sales 2020 130 B
EBIT 2020 55 209 M
Net income 2020 42 441 M
Finance 2020 13 373 M
Yield 2020 2,18%
P/E ratio 2020 23,0x
P/E ratio 2021 20,4x
EV / Sales2020 7,44x
EV / Sales2021 6,96x
Capitalization 979 B
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 416,21  DKK
Last Close Price 417,30  DKK
Spread / Highest target 19,8%
Spread / Average Target -0,26%
Spread / Lowest Target -30,5%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S7.93%141 503
JOHNSON & JOHNSON-8.02%345 705
ROCHE HOLDING AG2.77%277 060
MERCK & CO., INC-16.16%195 141
NOVARTIS-11.15%187 703
PFIZER, INC.-14.14%181 075